Palmitoylethanolamide (PEA)
Also sold as: Palmitoylethanolamide · Palmitoyl ethanolamide · Micronized PEA · Ultramicronized PEA
An endogenous fatty-acid amide studied mainly as an adjunct for chronic pain. Clinical findings concentrate on micronized or ultramicronized preparations and should not be generalized to every PEA powder or combination.
Energy
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Energy: Observational post-COVID fatigue findings are preliminary and disease-specific; no general energy benefit is established.
REALITY CHECK // PEA is not a universal natural painkiller. Large pooled pain effects coexist with heterogeneous evidence, some manufacturer-associated studies and limited independent head-to-head formulation trials. Neuroprotection and nerve repair remain unproven clinical claims; fatigue findings are observational post-COVID signals rather than a general energy effect.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No established EFSA/NIH UL is documented for PEA. The studied 300-1200 mg/day range is not an official upper safety limit, and short-term tolerability does not establish unlimited chronic use.
Summary
Chronic-pain meta-analyses favor PEA, but pooled effects vary substantially with diagnoses, preparations and trial quality. The 2023 analysis of 11 double-blind RCTs (n=774) reported a large pooled effect, SMD 1.68 (95% CI 1.05-2.31). Many other indications involve combinations, small studies or adjunctive treatment; pain relief and depression studies do not establish an anxiety benefit.
Mechanism
PEA is an endogenous lipid mediator proposed to modulate PPAR-alpha signaling, mast-cell/glial activation and inflammatory pain pathways. An endocannabinoid-related mechanism does not prove a clinical system reset or nerve regeneration.
Typical studied dose
The dossier describes 300-1200 mg/day in clinical studies, commonly 600-1200 mg/day, mainly micronized/ultramicronized oral PEA. Pain meta-analysis windows included 6-26 weeks. These are trial quantities, not a universal prescription; combination-product totals must not be treated as PEA mass.
Upper limit
No established EFSA/NIH UL is documented for PEA. The studied 300-1200 mg/day range is not an official upper safety limit, and short-term tolerability does not establish unlimited chronic use.
Popular stacks with Palmitoylethanolamide (PEA)
Not enough stack data yet. A combination with Palmitoylethanolamide (PEA) appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Ultramicronized palmitoylethanolamide Best for: Matching a major preparation category in chronic-pain trials. |
Extract weight · ~100% marker | 300–1200 mg | Clinical literature uses particle-reduced preparations; rat superiority over ordinary powder does not quantify human absorption. Usually tolerated; nausea, heaviness or diarrhea can occur. |
Studied standard [REFERENCE // CHECK_PREPARATION] Compare declared PEA compound mass. 100% refers to the named single ingredient, not a botanical marker or absorption rate. |
| Micronized palmitoylethanolamide Best for: Matching micronized clinical formulations. |
Extract weight · ~100% marker | 300–1200 mg | Often pooled with ultramicronized preparations; robust independent human superiority comparisons are lacking. Generally tolerated; persistent abdominal symptoms need assessment. |
Good option [GOOD // CHECK_PREPARATION] The 300-1200 mg/day range is dossier-wide, not proof that every pain diagnosis or formulation responds equally. |
| Nonmicronized PEA powder Best for: Identifying evidence-transfer limitations on a lower-cost product. |
Unstandardized: active content unknown | no comparable trial range | Poorly water-soluble lipid; rat comparison favored particle-reduced PEA, with limited human comparative data. Oral GI discomfort remains possible. |
Caution [CAUTION // CHECK_PREPARATION] No validated human preparation-specific range supplied; micronized efficacy is not automatically transferable. |
| Water-dispersible or liposomal PEA Best for: Identifying novel-delivery claims requiring stronger clinical validation. |
Unstandardized: active content unknown | no comparable trial range | A water-dispersible sciatica pilot is preliminary; liposomal delivery is not established as superior. Comparative tolerance data are sparse. |
Caution [CAUTION // CHECK_PREPARATION] No invented pilot dose or absorption multiplier; carrier/blend mass must not replace declared PEA mass. |
Common label traps
- TRAP_01 // Works for every pain like a drug
Mixed diagnoses, substantial heterogeneity and varying quality limit prediction for an individual. It is adjunctive evidence, not a universal replacement. - TRAP_02 // Micronization is either irrelevant or conclusively superior
Much clinical evidence uses particle-reduced PEA, but direct independent human head-to-head evidence is sparse. Rat data cannot settle the human comparison. - TRAP_03 // Repairs nerves or resets endocannabinoids
Mechanisms and preclinical neuroprotection do not establish human nerve regeneration or disease modification. - TRAP_04 // Endogenous means no adverse effects
Being a normal lipid mediator does not eliminate supplement-related GI symptoms or pregnancy-data gaps.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- Chronic pain Moderate · benefit
2023 double-blind RCT meta-analysis: 11 trials, n=774, pooled SMD 1.68 (95% CI 1.05-2.31; p=0.00001), favoring PEA. A 2025 synthesis of 18 RCTs, n=1196, reported SMDs -0.9 to -1.16 over 6-26 weeks. Sign conventions differ; heterogeneity, mixed preparations and manufacturer ties limit certainty.
PMID 36986081 PMID 39798151 PMID 26815246 PMID 28727699 PMID 36015298 - Neuropathic pain Moderate · benefit
The 2025 subgroup estimate was SMD -0.97 (95% CI -1.54 to -0.39), favoring PEA. Mixed causes and formulations limit generalization; neuropathy requires clinical assessment.
PMID 39798151 PMID 36015298 PMID 26815246 - Diabetic neuropathic pain Limited · benefit
Dedicated RCT/review evidence is limited; some studies are observational or use PEA with SOD, ALA, vitamins and minerals for 6 months, so isolated-PEA attribution is uncertain.
PMID 36057884 PMID 41664677 PMID 39339645 PMID 24804094 - Sciatica-related back pain Limited · benefit
A water-dispersible PEA pilot reported functional improvement; small preliminary evidence is not a confirmed treatment effect.
PMID 42255791 - Carpal tunnel syndrome Limited · benefit
Small studies, including open-label randomized work, report symptom signals; a dedicated placebo-effect study underscores uncertainty.
PMID 28299455 PMID 29676237 PMID 21483401 PMID 31993783 - Fibromyalgia adjunct Limited · benefit
PEA plus acetyl-L-carnitine was studied with duloxetine/pregabalin in women with fibromyalgia. Combination adjunct findings do not establish PEA monotherapy.
PMID 37378482 - Endometriosis pelvic pain Limited · benefit
Small pilot/open-label studies concern PEA-polydatin combinations or formulation comparisons. Findings do not identify an isolated-PEA effect.
PMID 21601979 PMID 31496832 - Migraine prevention Limited · benefit
Evidence includes a PEA-melatonin randomized trial, small nutraceutical studies, a pediatric tolerability pilot and an observational PEA-phycocyanin report. These are preparation-specific and preliminary.
PMID 40276532 PMID 35598579 PMID 32377286 PMID 42072406 - Knee osteoarthritis pain Limited · benefit
A placebo-controlled RCT and a newer multiple-baseline study involving probiotics/PEA provide limited symptom evidence; broad efficacy and superiority are not established.
PMID 30927159 PMID 41709243 - Major depression adjunct Limited · benefit
A small double-blind RCT added PEA to citalopram in major depression. This is specialist adjunctive evidence, not an anxiety or self-treatment claim.
PMID 29486338 - COVID-related inflammation, olfaction and fatigue Limited · benefit
A trial in recently diagnosed unvaccinated adults measured inflammatory markers; olfaction evidence involved luteolin and training, and fatigue/depression data in survivors were observational. Different populations and outcomes cannot be pooled into general energy efficacy.
PMID 36084236 PMID 37380908 PMID 35215365 PMID 38381905 - Neurodegeneration and multiple sclerosis No established evidence
Most neuroprotection evidence is preclinical. A relapsing-remitting MS trial addressed interferon-beta1a skin adverse effects/cytokines, not progression or regeneration; human disease modification is unestablished.
PMID 26857391 PMID 35625595 PMID 31396087 PMID 26055231
Reader questions
Is PEA the same as phenethylamine?
No. This card concerns palmitoylethanolamide, a fatty-acid amide. The shared abbreviation is not a reason to treat the substances or their doses as interchangeable.
Should I use ordinary, micronized or ultramicronized PEA?
Clinical pain evidence mainly concerns micronized/ultramicronized products. That supports matching studied preparations; it does not prove ultramicronized is always better in humans.
Can I replace my neuropathic-pain medication?
No substitution is established here. Neuropathy needs diagnosis; adjunctive PEA studies do not justify stopping prescribed treatment.
What if I get severe stomach pain?
Stop the product and seek assessment for severe or persistent pain. Mild GI effects are reported, but symptoms should not be dismissed because PEA is endogenous.
Stack interactions
- Caution Duloxetine, pregabalin and acetyl-L-carnitine [ADJUNCT // ATTRIBUTION_LIMIT]
A fibromyalgia RCT studied the combined adjunct; this is not evidence that isolated PEA replaces drugs or proves a separate synergy component.
PMID 37378482 - Caution Polydatin [COMBINATION // ATTRIBUTION_LIMIT]
Endometriosis pilot data concern PEA-polydatin combinations; benefit cannot be assigned to PEA alone.
PMID 21601979 PMID 31496832 - Caution Luteolin or melatonin [COMBINATION // ATTRIBUTION_LIMIT]
Post-COVID olfaction and migraine trials tested specific combinations. Melatonin also has its own sleep/timing effects.
PMID 37380908 PMID 40276532
Red flags: interactions and who should avoid it
Interactions
A fibromyalgia study added PEA plus acetyl-L-carnitine to duloxetine/pregabalin: any improvement is adjunctive and combination-specific. Polydatin, luteolin and melatonin trials do not isolate PEA or prove synergy. The dossier contains no established major CYP-mediated interaction, but sparse interaction data do not establish safety in all polypharmacy.
Avoid or ask a doctor first if
Pregnancy/breastfeeding safety is insufficient; rodent developmental or placental studies cannot establish human safety. Pediatric data are limited and require specialist supervision. Nausea, heaviness, diarrhea or abdominal pain may occur. Persistent severe abdominal pain requires assessment. Neuropathy, major depression, endometriosis and other disease-related pain require diagnosis and ongoing treatment.
Sources (PubMed, 14)
- Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.
PMID 36986081 · 2023 · systematic review and meta-analysisEleven double-blind chronic-pain RCTs with a large but heterogeneous pooled signal.
- Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding.
PMID 39798151 · 2025 · systematic review and meta-analysisNewer pain meta-analysis including neuropathic subgroup estimate and chronic evaluation windows.
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain.
PMID 36057884 · 2022 · randomized controlled trialDedicated randomized evidence in diabetic peripheral neuropathic pain.
- Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
PMID 25164769 · 2014 · animal studyRat formulation comparison; not a human bioavailability superiority trial.
- Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study.
PMID 37378482 · 2023 · randomized controlled trialCombination adjunct to duloxetine/pregabalin in fibromyalgia.
- Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study.
PMID 21601979 · 2011 · randomized controlled trialPilot PEA-transpolydatin evidence for endometriosis pain, not isolated PEA.
- Fixed combination of palmitoylethanolamide and melatonin in preventive therapy of migraine: results from a randomized clinical trial.
PMID 40276532 · 2025 · randomized controlled trialMigraine prevention trial of a fixed PEA-melatonin combination.
- A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
PMID 30927159 · 2019 · randomized controlled trialPlacebo-controlled knee-osteoarthritis symptom trial.
- Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
PMID 29486338 · 2018 · randomized controlled trialSmall randomized adjunctive trial in major depressive disorder.
- Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial.
PMID 36084236 · 2022 · randomized controlled trialInflammatory-marker RCT in unvaccinated adults recently diagnosed with COVID-19.
- Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial.
PMID 37380908 · 2023 · randomized controlled trialRandomized post-COVID olfaction study with luteolin and/or olfactory training.
- Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors.
PMID 38381905 · 2024 · cohort studyObservational fatigue/depression findings in COVID survivors.
- Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
PMID 26857391 · 2016 · randomized controlled trialMS adjunct study of interferon-related skin effects/cytokines, not progression.
- Water-Dispersible Palmitoylethanolamide (PEA) Supplementation for Functional Improvement in Adults With Chronic Sciatica-Related Back Pain: A Pilot Clinical Trial.
PMID 42255791 · 2026 · clinical studyPreliminary water-dispersible PEA sciatica pilot.
Community comments
No approved comments yet. Comments are held for moderation.